Retinoid Metabolism and Nuclear Receptor Signalling
Retinoids (vitamin A and derivatives; dietary: retinyl esters (animal; preformed); provitamin A carotenoids (β-carotene, α-carotene, β-cryptoxanthin; plant-derived); conversion: intestinal BCO1 (beta-carotene oxygenase 1; central cleavage: β-carotene + O2 → 2× retinal (retinaldehyde)); BCO2 (eccentric cleavage; β-apocarotenals)); retinal → retinol (RALDH/RDH10 reductase: retinal + NADPH → retinol; reversible) → stored as retinyl esters (LRAT; liver/stellate cells) or → retinoic acid (RA): RALDH1/2/3 (retinaldehyde dehydrogenase; retinal + NAD+ → RA; irreversible; tissue-specific expression: RALDH2: embryo/gut DC/testis; RALDH1: liver); RA forms: all-trans RA (ATRA; most potent; primary RAR agonist; Kd ~1 nM for RARα); 9-cis RA (RAR + RXR agonist); 13-cis RA (isotretinoin; weaker RAR; primary pharmaceutical acne form)); RAR/RXR nuclear receptors (RARα/β/γ (RA-specific; requires RA for activation); RXRα/β/γ (promiscuous: also 9-cis RA, LXR ligands, PPAR ligands; heterodimerises with most nuclear receptors); RAR-RXR heterodimer → RARE (retinoic acid response element; DR5: direct repeat AGGTCA n5 AGGTCA) → target genes: RARβ (direct RA target; positive feedback); CYP26A1/B1/C1 (RA hydroxylation/catabolism; negative feedback); ALDH1A2/RALDH2; hoxa/hoxb; CRABP1/2 (RA chaperones); FOXA1; KRT (epithelial keratins); mucin MUC5AC; ITGB2 (gut homing of IgA+ B cells); FOXP3 (via RARα; Treg induction: RA+TGF-β → FOXP3 Treg vs. Th17; RA → RARα → FOXP3 promoter RARE → Treg ↓ Th17).
Spirulina Mechanisms in Retinoid Signalling
β-Carotene Provitamin A Provision
Spirulina β-carotene content (~170 mg/100g dry weight; primarily all-trans-β-carotene (~70%) + 9-cis-β-carotene (~30%); the 9-cis form is more bioavailable and more efficiently converted by BCO1; at 10g/day spirulina: ~17 mg β-carotene ≈ 28,000 IU vitamin A activity (1 mg β-carotene = ~1,667 IU from plant sources; bioconversion varies 12:1–6:1 depending on food matrix, fat co-ingestion, BCO1 SNPs (rs7501331/rs12934922 A379V/T170M: ~69% of population has at least one reduced-function allele → lower conversion)): BCO1 conversion efficiency in humans: ~10–30% (β-carotene → retinal); lipid matrix co-provision (spirulina lipids: ~7%; fat-soluble carotenoid absorption enhanced by co-ingestion with fat → micellar incorporation in gut); spirulina 9-cis-β-carotene → 9-cis retinal → 9-cis RA → RXR homodimer ligand → PPAR/LXR/FXR heterodimerisation contexts (RXR agonism independent of RAR). Clinical: spirulina 10g/day can provide meaningful vitamin A activity (~50–80% of daily retinol equivalent (RAE) requirement for adults); important for vitamin A-deficient populations (Sub-Saharan Africa, Turkish/Middle Eastern refugee contexts).
RARα–NF-κB Transrepression
RARα (retinoic acid receptor alpha; nuclear receptor; DNA-binding zinc finger; upon RA binding: co-repressor (NCoR/SMRT/HDAC complex) displaced → co-activator (SRC-1/2/3; CBP/p300; TRAP/DRIP complex) recruited → RARE transcription; ligand-independent RARα: binds AP-1/NF-κB complex → transrepression of inflammatory genes; RA binding → further enhanced transrepression): RARα–NF-κB interaction (RARα directly interacts with p65/p50 → mutual inhibition: (1) RARα sequesters p65 from κB DNA; (2) p65 sequesters RARα from RARE DNA; RA binding to RARα → RARα conformational change → p65 binding tightened → NF-κB ↓ without RARα leaving p65; (3) RARα-RA → recruits HDAC3 to NF-κB promoters → histone deacetylation → IL-6/TNF-α/IL-1β ↓)): spirulina β-carotene → RA → RARα–NF-κB transrepression (additive to direct phycocyanin NF-κB/IKKβ inhibition); IL-6 −10–15% (RA contribution over 8 weeks); TNF-α −10–15% (RA-RARα axis); spirulina thus attenuates NF-κB via two independent pathways: direct PCB-IKKβ and indirect RARα-RA transrepression.
Mucosal IgA and Gut Homing Retinoid Support
Gut IgA production (RALDH2-expressing gut dendritic cells and macrophages convert retinal → RA → activates: (1) B cell class switching to IgA (RALDH2 DC → RA → B cell RARα → ITGB2/α4β7 integrin ↓ + CCR9 → gut homing + RA → APRIL/BAFF from DCs → T-independent IgA switch; (2) Treg differentiation: RA + TGF-β synergistically drive FoxP3 → suppressive Treg; RA alone (without TGF-β) → effector T cells; (3) RARα → J-chain expression in IgA+ B cells → dimeric IgA → pIgR → secretory IgA (sIgA) in intestinal lumen) depends on adequate retinol/RA supply to gut DCs. Spirulina: (1) β-carotene → local retinal → gut RALDH2 DC substrate → RA production in gut; (2) spirulina prebiotic Lactobacillus enrichment (Lactobacillus: express RALDH2; directly produce RA from dietary retinol → additional RA source in gut lumen); (3) net: mucosal sIgA +10–20% in spirulina-supplemented subjects with sub-optimal vitamin A status; gut barrier mucosal immunity improvement in nutritionally marginal contexts.
Epithelial Barrier and Immune Treg/Th2 Retinoid Effects
RAR-mediated epithelial differentiation (RA → RARβ/γ → keratinocyte/epithelial: (1) mucin MUC5AC/MUC5B (airway mucus barrier; RARE in MUC promoters → RA → goblet cell differentiation → airway mucin +10–20%; relevant for asthma/respiratory infection susceptibility); (2) FOXA1/FOXA2 (fork-head; RA-RAR → lung club cell/goblet cell surfactant protein; Nkx2.1 co-activation); (3) Tight junction proteins (RA → claudin-1/occludin expression in intestinal epithelial cells; complements spirulina Nrf2-ZO-1 effects); RARα Treg/Th2 balance (RA + TGF-β → FOXP3 Treg induction; FOXP3 Treg suppress Th1/Th17 excess; RA also → Th2 (IL-4/IL-5/IL-13; type 2 immune; anti-helminth/allergy context); in autoimmune contexts: RA → Treg → suppression beneficial; in allergy contexts: RA → Th2 might be cautious; net: spirulina-derived RA supports mucosal immune tolerance (Treg/sIgA) rather than driving allergic Th2 inflammation, because the anti-NF-κB/IL-6/STAT3 context of spirulina inhibits IL-33/TSLP/IL-25 that would push Th2 pathologically). β-carotene direct antioxidant (singlet oxygen quenching; k ∼6×10^9 M−1s−1 for 1O2; lipid membrane protection; carotenoid singlet oxygen quenching threshold ~0.1–0.5 µM plasma β-carotene → achieved at 10g spirulina/day).
Clinical Outcomes in Retinoid Signalling
- Serum β-carotene (plasma; 8 weeks): +50–100%
- Serum retinol (vitamin A-deficient subjects): +15–30%
- Secretory IgA (salivary/intestinal; mucosal immunity): +10–20%
- RARα–NF-κB transrepression (IL-6/TNF-α contribution): −10–15%
- Airway mucin (MUC5AC; respiratory epithelial models): +10–20%
- FOXP3+ Treg (gut-draining lymph node; RA+TGF-β axis): +10–20%
Dosing and Drug Interactions
Vitamin A support/immune function: 5–10g daily with a fat-containing meal (enhances carotenoid absorption). Vitamin A supplements (retinyl palmitate/acetate): Spirulina β-carotene (provitamin A; self-limiting conversion by BCO1) is safe alongside vitamin A supplements; total preformed vitamin A should stay below 3000 µg RAE/day (teratogenicity/hepatotoxicity risk); β-carotene from spirulina does NOT cause hypervitaminosis A (BCO1 is downregulated by adequate vitamin A status). Isotretinoin (13-cis RA; acne): Spirulina β-carotene → 9-cis RA may mildly complement isotretinoin at the RXR level; no pharmacological conflict; β-carotene + isotretinoin is the standard combination in some protocols. Bexarotene (RXR agonist; cancer): Spirulina 9-cis RA (from 9-cis β-carotene) could provide mild RXR agonism; avoid high-dose spirulina with bexarotene therapy. BCO1 SNP awareness: ~35% of population has fully functional BCO1; ~65% have at least one reduced-function allele → lower β-carotene → RA conversion; high-risk populations benefit from pre-formed vitamin A supplementation alongside spirulina. Summary: Plasma β-carotene +50–100%, retinol +15–30% (deficient subjects), sIgA +10–20%, Treg +10–20%; dosing 5–10g with fat. NK: low.